RATIO OF METASTATIC LYMPH NODES VS. RESECTED LYMPH NODES (N-RATIO) HAS PROGNOSTIC IMPLICATIONS IN GASTRIC CANCER.


Journal

Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery
ISSN: 2317-6326
Titre abrégé: Arq Bras Cir Dig
Pays: Brazil
ID NLM: 9100283

Informations de publication

Date de publication:
2024
Historique:
received: 19 02 2024
accepted: 20 06 2024
medline: 25 9 2024
pubmed: 25 9 2024
entrez: 25 9 2024
Statut: epublish

Résumé

Lymph node status is vital for gastric cancer (GC) prognosis, but the conventional pN stage may be limited by variations in lymphadenectomy and stage migration. The N-Ratio, which assesses the ratio of metastatic to resected lymph nodes, emerges as a promising prognostic tool. To assess N-Ratios prognostic value in GC, particularly in patients with <25 resected lymph nodes. Patients who underwent gastrectomy with curative intent for GC were retrospectively evaluated. The N-Ratio categories were determined using the ROC curve method, and the area under the curve (AUC) was used as a measure of performance in predicting recurrence/death. A total of 561 GC patients were included in the study, 57% had pN+ status, and 17.5% had <25 resected lymph nodes. N-Ratio, with a mean of 0.12, predicted survival with 74% accuracy (AUC=0.74; 95%CI 0.70-0.78, p<0.001). N-Ratio categories included: N-Ratio 0 (43%); N-Ratio 1 (12.3%); N-Ratio 2 (31.6%); and N-Ratio 3 (13.2%). Disease-free survival (DFS) varied among all N-Ratio groups, with N-Ratio 3 showing worse survival than pN3 cases (DFS=21.8 vs. 11 months, p=0.022, p<0.05). In cases with <25 resected lymph nodes, DFS was not significantly worse in N-Ratio 0 (68.8 vs. 81.9%, p=0.061, p>0.05) and N-Ratio 1 (66.2 vs. 50%, p=0.504, p>0.05) groups. The DFS of N-Ratio-0 cases with <25 lymph nodes was similar to N-Ratio 1 cases. N-Ratio influenced survival in GC patients, especially in advanced lymph node disease (N-Ratio 3). Considering that N-Ratio does not impact pN0 cases, individualized prognosis assessment is essential for patients with <25 resected lymph nodes.

Sections du résumé

BACKGROUND BACKGROUND
Lymph node status is vital for gastric cancer (GC) prognosis, but the conventional pN stage may be limited by variations in lymphadenectomy and stage migration. The N-Ratio, which assesses the ratio of metastatic to resected lymph nodes, emerges as a promising prognostic tool.
AIMS OBJECTIVE
To assess N-Ratios prognostic value in GC, particularly in patients with <25 resected lymph nodes.
METHODS METHODS
Patients who underwent gastrectomy with curative intent for GC were retrospectively evaluated. The N-Ratio categories were determined using the ROC curve method, and the area under the curve (AUC) was used as a measure of performance in predicting recurrence/death.
RESULTS RESULTS
A total of 561 GC patients were included in the study, 57% had pN+ status, and 17.5% had <25 resected lymph nodes. N-Ratio, with a mean of 0.12, predicted survival with 74% accuracy (AUC=0.74; 95%CI 0.70-0.78, p<0.001). N-Ratio categories included: N-Ratio 0 (43%); N-Ratio 1 (12.3%); N-Ratio 2 (31.6%); and N-Ratio 3 (13.2%). Disease-free survival (DFS) varied among all N-Ratio groups, with N-Ratio 3 showing worse survival than pN3 cases (DFS=21.8 vs. 11 months, p=0.022, p<0.05). In cases with <25 resected lymph nodes, DFS was not significantly worse in N-Ratio 0 (68.8 vs. 81.9%, p=0.061, p>0.05) and N-Ratio 1 (66.2 vs. 50%, p=0.504, p>0.05) groups. The DFS of N-Ratio-0 cases with <25 lymph nodes was similar to N-Ratio 1 cases.
CONCLUSIONS CONCLUSIONS
N-Ratio influenced survival in GC patients, especially in advanced lymph node disease (N-Ratio 3). Considering that N-Ratio does not impact pN0 cases, individualized prognosis assessment is essential for patients with <25 resected lymph nodes.

Identifiants

pubmed: 39319897
pii: S0102-67202024000100316
doi: 10.1590/0102-6720202400031e1824
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1824

Auteurs

Breno Cordeiro Porto (BC)

Universidade de São Paulo, School of Medicine, Cancer Institute of the State of São Paulo - São Paulo (SP), Brazil.

Marina Alessandra Pereira (MA)

Universidade de São Paulo, School of Medicine, Cancer Institute of the State of São Paulo - São Paulo (SP), Brazil.

Marcus Fernando Kodama Pertille Ramos (MFKP)

Universidade de São Paulo, School of Medicine, Cancer Institute of the State of São Paulo - São Paulo (SP), Brazil.

André Roncon Dias (AR)

Universidade de São Paulo, School of Medicine, Cancer Institute of the State of São Paulo - São Paulo (SP), Brazil.

Fábio Pinatel Lopasso (FP)

Universidade de São Paulo, School of Medicine, Cancer Institute of the State of São Paulo - São Paulo (SP), Brazil.

Luiz Augusto Carneiro D'Albuquerque (LAC)

Universidade de São Paulo, School of Medicine, Cancer Institute of the State of São Paulo - São Paulo (SP), Brazil.

Ulysses Ribeiro Junior (U)

Universidade de São Paulo, School of Medicine, Cancer Institute of the State of São Paulo - São Paulo (SP), Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH